Improving the Timeliness of Chemotherapy Administration in the Bone Marrow Transplant Unit.


Journal

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628

Informations de publication

Date de publication:
01 2020
Historique:
received: 09 05 2019
revised: 19 09 2019
accepted: 20 09 2019
pubmed: 29 9 2019
medline: 22 1 2021
entrez: 29 9 2019
Statut: ppublish

Résumé

Patients undergoing hematopoietic stem cell transplantation (HSCT) are often admitted to the hospital the day they are due to begin their conditioning regimen. Timely initiation of chemotherapy during regular work hours is important for patient safety, because during the night shift fewer physicians and pharmacists are available for urgent or unexpected matters. A review of the data at our institution from October 2017 to August 2018 showed that approximately one-third of our chemotherapy was started during the night shift (after 19:00), and the average time from admission to start of chemotherapy was over 8 hours. There are currently no well-defined benchmarks for timeliness of chemotherapy initiation. The aim of this quality improvement initiative was to increase the percentage of patients who start chemotherapy in the bone marrow transplant unit before 19:00 from 65% to >80% by March 31, 2019. We identified barriers to timely initiation of chemotherapy through process mapping and analysis of failures. The primary barriers were late admissions (after 12:00 pm) and time from admission to preparation of chemotherapy. We addressed mechanisms to mitigate these barriers through Plan-Do-Study-Act testing. Interventions included providing families specific admission times and their rationales and process for notifying pharmacy of admissions immediately on arrival. We used standardized control charts to measure the impact of the interventions on change. We also monitored medication errors before and during the intervention. From September 2018 to March 2019 the percentage of patients who started preparative chemotherapy before 19:00 increased from 65% to 85%, the percentage of patients who were admitted after 12:00 remained similar before (31%) and after the interventions (33%), and the average time from admission to start of chemotherapy decreased from 8.6 hours (513 minutes) to 6.4 hours (382 minutes). Medication errors were similar before (n = 50) and after the interventions (n = 43). Using standardized processes, we demonstrated a substantial decrease in the percentage of HSCT patients starting their preparative regimen after 19:00 without a concurrent increase in errors. We believe these interventions and measurements can be used in all transplant centers and have the potential to influence patient safety and outcomes.

Identifiants

pubmed: 31562961
pii: S1083-8791(19)30637-8
doi: 10.1016/j.bbmt.2019.09.026
pmc: PMC7513385
mid: NIHMS1621015
pii:
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

150-156

Subventions

Organisme : NCI NIH HHS
ID : P30 CA014089
Pays : United States

Informations de copyright

Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Références

J Infus Nurs. 2019 Jul/Aug;42(4):183-192
pubmed: 31283660
Lancet. 2019 Jul 27;394(10195):283-285
pubmed: 31272692
Qual Saf Health Care. 2003 Dec;12(6):458-64
pubmed: 14645763
BMJ. 1996 Mar 9;312(7031):619-22
pubmed: 8595340
J Oncol Pract. 2017 Apr;13(4):e329-e336
pubmed: 28260404
JAMA. 2001 Apr 25;285(16):2114-20
pubmed: 11311101
Pediatrics. 2002 Oct;110(4):737-42
pubmed: 12359787
Arch Dis Child. 2005 Jul;90(7):698-702
pubmed: 15970610
N Engl J Med. 1991 Feb 7;324(6):377-84
pubmed: 1824793
Mayo Clin Proc. 2007 Jun;82(6):735-9
pubmed: 17550754
Qual Manag Health Care. 2001 Spring;9(3):1-27
pubmed: 11372500
BMJ Qual Saf. 2016 Dec;25(12):986-992
pubmed: 26369893
J Pediatr Nurs. 2004 Dec;19(6):385-92
pubmed: 15637579
BMJ Qual Saf. 2013 Nov;22(11):899-906
pubmed: 23744537
N Engl J Med. 1991 Feb 7;324(6):370-6
pubmed: 1987460
JAMA. 2014 May 7;311(17):1731-2
pubmed: 24794361
JAMA. 1991 Jun 26;265(24):3265-9
pubmed: 2046108

Auteurs

Rusha Bhandari (R)

Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital of Los Angeles, Los Angeles, California; Keck School of Medicine, University of Southern California, Los Angeles, California. Electronic address: rbhandari@chla.usc.edu.

Etan Orgel (E)

Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital of Los Angeles, Los Angeles, California; Keck School of Medicine, University of Southern California, Los Angeles, California.

Teresa Rushing (T)

Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital of Los Angeles, Los Angeles, California; Department of Pharmacy, Children's Hospital of Los Angeles, Los Angeles, California.

Kristin Malicse (K)

Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital of Los Angeles, Los Angeles, California; Keck School of Medicine, University of Southern California, Los Angeles, California.

Vilma Evangelista (V)

Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Hospital of Los Angeles, Los Angeles, California; Keck School of Medicine, University of Southern California, Los Angeles, California.

Sonata Jodele (S)

Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati, Ohio; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.

Christopher E Dandoy (CE)

Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati, Ohio; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; James M. Anderson Center for Health Systems Excellence, Cincinnati, Ohio.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH